Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge

Journal of Virology

Volumn 80, Issue 9, 2006, Pages 4447-4457

  Natuk, Robert J ^a   Cooper, David ^a   Guo, Min ^a   Calderon, Priscilla ^a   Wright, Kevin J ^a   Nasar, Farooq ^a   Witko, Susan ^a   Pawlyk, Diane ^a   Lee, Margaret ^a   DeStefano, Joanne ^a   Tummolo, Donna ^a   Abramovitz, Aaron S ^a   Gangolli, Seema ^a   Kalyan, Narender ^a   Clarke, David K ^a   Hendry, R Michael ^a   Eldridge, John H ^a   Udem, Stephen A ^a   Kowalski, Jacek ^a  

^a WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN D; GLYCOPROTEIN D ANTIBODY; HERPES VACCINE; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADOLESCENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; FEMALE; GENITAL HERPES; GUINEA PIG; HERPES SIMPLEX VIRUS 2; IMMUNE RESPONSE; IMMUNOGENICITY; LATENT VIRUS INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPINAL GANGLION; TH1 CELL; VACCINATION; VAGINITIS; VESICULAR STOMATITIS VIRUS; VIRUS GENOME; VIRUS RECOMBINANT;

ANIMALS; ANTIBODY FORMATION; FEMALE; GENETIC VECTORS; GLYCOPROTEINS; GUINEA PIGS; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 2, HUMAN; MICE; MODELS, ANIMAL; TH1 CELLS; VAGINA; VESICULAR STOMATITIS-INDIANA VIRUS; VIRAL ENVELOPE PROTEINS;

CAVIA; CAVIA PORCELLUS; HUMAN HERPESVIRUS 2; MURINAE; VESICULAR STOMATITIS VIRUS;

EID: 33646181263     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.80.9.4447-4457.2006     Document Type: Article

References (72)

1. Aurelian, L., H. Kokuba, and C. C. Smith. 1999. Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10). Vaccine 17:1951-1963.
2. Balachandran, N., S. Bacchetti, and W. E. Rawls. 1982. Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2. Infect. Immun. 37:1132-1137.
3. Bernstein, D. I. 2000. Effect of route of vaccination with vaccinia virus expressing HSV-2 glycoprotein D on protection from genital HSV-2 infection. Vaccine 18:1351-1358.
4. Blakeney, S., J. Kowalski, D. Tummolo, J. DeStefano, D. Cooper, M. Guo, S. Gangolli, D. Long, T. Zamb, R. J. Natuk, and R. J. Visalli. 2005. Herpes simplex virus type 2 UL24 gene is a virulence determinant in murine and guinea pig disease models. J. Virol. 79:10498-10506.
5. Buonocore, L., K. J. Blight, C. M. Rice, and J. K. Rose. 2002. Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins. J. Virol. 76:6865-6872.
6. + CTL clones specific for the glycoprotein of vesicular stomatitis virus. Cell. Immunol. 146:147-156.
7. Celum, C., R. Levine, M. Weaver, and A. Wald. 2004. Genital herpes and human immunodeficiency virus: double trouble. Bull. W. H. O. 82:447-453.
8. Chabalgoity, J. A., C. M. Khan, A. A. Nash, and C. E. Hormaeche. 1996. A Salmonella typhimurium htrA live vaccine expressing multiple copies of a peptide comprising amino acids 8-23 of herpes simplex virus glycoprotein D as a genetic fusion to tetanus toxin fragment C protects mice from herpes simplex virus infection. Mol. Microbiol. 19:791-801.
9. + CTL responses. Vaccine 23:236-246.
10. Corey, L., A. G. Langenberg, R. Ashley, R. E. Sekulovich, A. E. Izu, J. M. Douglas, Jr., H. H. Handsfield, T. Warren, L. Marr, S. Tyring, R. DiCarlo, A. A. Adimora, P. Leone, C. L. Dekker, R. L. Burke, W. P. Leong, S. E. Straus, et al. 1999. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. JAMA 282:331-340.
11. Cotton, W. E. 1926. Vesicular stomatitis in its relation to the diagnosis of foot-and-mouth disease. J. Am. Vet. Med. Assoc. 69:313-332.
12. Da Costa, X. J., N. Bourne, L. R. Stanberry, and D. M. Knipe. 1997. Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease. Virology 232:1-12.
13. Egan, M. A., S. Y. Chong, N. F. Rose, S. Megati, K. J. Lopez, E. B. Schadeck, J. E. Johnson, A. Masood, P. Piacente, R. E. Druilhet, P. W. Barras, D. L. Hasselschwert, P. Reilly, E. M. Mishkin, D. C. Montefiori, M. G. Lewis, D. K. Clarke, R. M. Hendry, P. A. Marx, J. H. Eldridge, S. A. Udem, Z. R. Israel, and J. K. Rose. 2004. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes. AIDS Res. Hum. Retrovir. 20:989-1004.
14. Flanagan, E. B., J. M. Zamparo, L. A. Ball, L. L. Rodriguez, and G. W. Wertz. 2001. Rearrangement of the genes of vesicular stomatitis virus eliminates clinical disease in the natural host: new strategy for vaccine development. J. Virol. 75:6107-6114.
15. Fleming, D. T., G. M. McQuillan, R. E. Johnson, A. J. Nahmias, S. O. Aral, F. K. Lee, and M. E. St. Louis. 1997. Herpes simplex virus type 2 in the United States, 1976 to 1994. N. Engl. J. Med. 337:1105-1111.
16. Fukushi, S., T. Mizutani, M. Saijo, S. Matsuyama, N. Miyajima, F. Taguchi, S. Itamura, I. Kurane, and S. Morikawa. 2005. Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein. J. Gen. Virol. 86:2269-2274.
17. Gallichan, W. S., and K. L. Rosenthal. 1998. Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization. J. Infect. Dis. 177:1155-1161.
18. Garbutt, M., R. Liebscher, V. Wahl-Jensen, S. Jones, P. Moller, R. Wagner, V. Volchkov, H. D. Klenk, H. Feldmann, and U. Stroher. 2004. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J. Virol. 78:5458-5465.
19. Geisbert, T. W., S. Jones, E. A. Fritz, A. C. Shurtleff, J. B. Geisbert, R. Liebscher, A. Grolla, U. Stroher, L. Fernando, K. M. Daddario, M. C. Guttieri, B. R. Mothe, T. Larsen, L. E. Hensley, P. B. Jahrling, and H. Feldmann. 2005. Development of a new vaccine for the prevention of Lassa fever. PLoS Med. 2:e183.
20. Grigera, P. R., M. P. Marzocca, A. V. Capozzo, L. Buonocore, R. O. Donis, and J. K. Rose. 2000. Presence of bovine viral diarrhea virus (BVDV) E2 glycoprotein in VSV recombinant particles and induction of neutralizing BVDV antibodies in mice. Virus Res. 69:3-15.
21. Heineman, T. C., L. Pesnicak, M. A. Ali, T. Krogmann, N. Krudwig, and J. I. Cohen. 2004. Varicella-zoster virus expressing HSV-2 glycoproteins B and D induces protection against HSV-2 challenge. Vaccine 22:2558-2565.
22. Hoshino, Y., S. K. Dalai, K. Wang, L. Pesnicak, T. Y. Lau, D. M. Knipe, J. I. Cohen, and S. E. Straus. 2005. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J. Virol. 79:410-418.
23. Inoue, Y., Y. Ohashi, H. Watanabe, and R. Manabe. 1992. Protective effects of anti-glycoprotein D monoclonal antibodies in murine herpetic keratitis. Curr. Eye Res. 11:53-60.
24. Ishizaka, S. T., P. Piacente, J. Silva, and E. M. Mishkin. 1995. IgG subtype is correlated with efficiency of passive protection and effector function of anti-herpes simplex virus glycoprotein D monoclonal antibodies. J. Infect. Dis. 172:1108-1111.
25. - cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins. J. Virol. 71:5060-5068.
26. Jones, S. M., H. Feldmann, U. Stroher, J. B. Geisbert, L. Fernando, A. Grolla, H. D. Klenk, N. J. Sullivan, V. E. Volchkov, E. A. Fritz, K. M. Daddario, L. E. Hensley, P. B. Jahrling, and T. W. Geisbert. 2005. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11:786-790.
27. Kahn, J. S., M. J. Schnell, L. Buonocore, and J. K. Rose. 1999. Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion. Virology 254:81-91.
28. Kapadia, S. U., J. K. Rose, E. Lamirande, L. Vogel, K. Subbarao, and A. Roberts. 2005. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology.
29. Karem, K. L., J. Bowen, N. Kuklin, and B. T. Rouse. 1997. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens. J. Gen. Virol. 78(Pt. 2):427-434.
30. Kelley, J. M., S. U. Emerson, and R. R. Wagner. 1972. The glycoprotein of vesicular stomatitis virus is the antigen that gives rise to and reacts with neutralizing antibody. J. Virol. 10:1231-1235.
31. Koszinowski, U., and G. Bandlow. 1975. Induction and in Vitro demonstration of cellular immunity to DNA and RNA viruses in guinea-pigs. Clin. Exp. Immunol. 20:143-154.
32. Kovacs, G. R., C. L. Parks, N. Vasilakis, and S. A. Udem. 2003. Enhanced genetic rescue of negative-strand RNA viruses: use of an MVA-T7 RNA polymerase vector and DNA replication inhibitors. J. Virol. Methods 111: 29-36.
33. Lawson, N. D., E. A. Stillman, M. A. Whitt, and J. K. Rose. 1995. Recombinant vesicular stomatitis viruses from DNA. Proc. Natl. Acad. Sci. USA 92:4477-4481.
34. Long, D., T. J. Madara, M. Ponce de Leon, G. H. Cohen, P. C. Montgomery, and R. J. Eisenberg. 1984. Glycoprotein D protects mice against lethal challenge with herpes simplex virus types 1 and 2. Infect. Immun. 43:761-764.
35. - T-cell subsets during virus infection. Protective capacity depends on effector cytokine secretion and on migratory capability. J. Exp. Med. 191:2159-2170.
36. Manning, W. C., X. Paliard, S. Zhou, M. Pat Bland, A. Y. Lee, K. Hong, C. M. Walker, J. A. Escobedo, and V. Dwarki. 1997. Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D. J. Virol. 71:7960-7962.
37. Martin, S., B. Moss, P. W. Herman, L. A. Laskey, and B, T. Rouse. 1987. Mechanisms of antiviral immunity induced by a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: cytotoxic T cells. J. Virol. 61:726-734.
38. Martin, S., and B. T. Rouse. 1987. The mechanisms of antiviral immunity induced by a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: clearance of local infection. J. Immunol. 138:3431-3437.
39. McClements, W. L., M. E. Armstrong, R. D. Keys, and M. A. Liu. 1996. Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. Proc. Natl. Acad. Sci. USA 93:11414-11420.
40. McDermott, M. R., J. R. Smiley, P. Leslie, J. Brais, H. E. Rudzroga, and J. Bienenstock. 1984. Immunity in the female genital tract after intravaginal vaccination of mice with an attenuated strain of herpes simplex virus type 2. J. Virol. 51:747-753.
41. Meseda, C. A., K. L. Elkins, M. J. Merchlinsky, and J. P. Weir. 2002. Prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone. J. Infect. Dis. 186:1065-1073.
42. Olitsky, P. K., J. Traum, and H. W. Schoening. 1926. Comparative studies on vesicular stomatitis and foot-and-mouth disease. J. Am. Vet. Med. Assoc. 79:147-167.
43. Parks, C. L., R. A. Lerch, P. Walpita, M. S. Sidhu, and S. A. Udem. 1999. Enhanced measles virus cDNA rescue and gene expression after heat shock. J. Virol. 73:3560-3566.
44. Parr, M. B., L. Kepple, M. R. McDermott, M. D. Drew, J. J. Bozzola, and E. L. Parr. 1994. A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2. Lab. Investig. 70:369-380.
45. Prichard, M. N., R. Kaiwar, W. T. Jackman, D. C. Quenelle, D. J. Collins, E. R. Kern, G. M. Kemble, and R. R. Spaete. 2005. Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs. Vaccine 23:5424-5431.
46. Publicover, J., E. Ramsburg, and J. K. Rose. 2004. Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses. J. Virol. 78:9317-9324.
47. Reuter, J. D., B. E. Vivas-Gonzalez, D. Gomez, J. H. Wilson, J. L. Brandsma, H. L. Greenstone, J. K. Rose, and A. Roberts. 2002. Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease. J. Virol. 76:8900-8909.
48. Roberts, A., L. Buonocore, R. Price, J. Forman, and J. K. Rose. 1999. Attenuated vesicular stomatitis viruses as vaccine vectors. J. Virol. 73:3723-3732.
49. Roberts, A., E. Kretzschmar, A. S. Perkins, J. Forman, R. Price, L. Buonocore, Y. Kawaoka, and J. K. Rose. 1998. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J. Virol. 72:4704-4711.
50. Roberts, A., J. D. Reuter, J. H. Wilson, S. Baldwin, and J. K. Rose. 2004. Complete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein. J. Virol. 78:3196-3199.
51. Rose, J. K., and M. A. Whitt. 2001. Rhabdoviridae: the viruses and their replication, p. 1221-1244. In D. M. Knipe and P. M. Howley (ed.), Fields virology, 4th ed. Lippincott/The Williams & Wilkins Co., Philadelphia, Pa.
52. Rose, N. F., P. A. Marx, A. Luckay, D. F. Nixon, W. J. Moretto, S. M. Donahoe, D. Montefiori, A. Roberts, L. Buonocore, and J. K. Rose. 2001. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106:539-549.
53. Rose, N. F., A. Roberts, L. Buonocore, and J. K. Rose. 2000. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1. J. Virol. 74:10903-10910.
54. Sabin, A. B., and P. K. Olitsky. 1938. Influence of host factors on neuroinvasiveness of vesicular stomatitis virus. IV. Variations in neuroinvasiveness in different species. J. Exp. Med. 67:229-249.
55. Sanna, P. P., A. De Logu, R. A. Williamson, Y. L. Horn, S. E. Straus, F. E. Bloom, and D. R. Burton. 1996. Protection of nude mice by passive immunization with a type-common human recombinant monoclonal antibody against HSV. Virology 215:101-106.
56. Schlereth, B., J. K. Rose, L. Buonocore, V. ter Meulen, and S. Niewiesk. 2000. Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies. J. Virol. 74:4652-4657.
57. Schnell, M. J., L. Buonocore, E. Kretzschmar, E. Johnson, and J. K. Rose. 1996. Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc. Natl. Acad. Sci. USA 93:11359-11365.
58. Schnell, M. J., L. Buonocore, M. A. Whitt, and J. K. Rose. 1996. The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. J. Virol. 70:2318-2323.
59. She, J., M. C. Ruzek, P. Velupillai, I. de Aos, B. Wang, D. A. Harn, J. Sancho, C. A. Biron, and C. Terhorst. 1999. Generation of antigen-specific cytotoxic T lymphocytes and regulation of cytokine production takes place in the absence of CD3Cζ. Int. Immunol. 11:845-857.
60. Sin, J. I., J. J. Kim, J. D. Boyer, R. B. Ciccarelli, T. J. Higgins, and D. B. Weiner. 1999. In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model. J. Virol. 73:501-509.
61. Skinner, H. H. 1957. The virus of vesicular stomatitis in small experimental hosts. II. Guinea pigs and rabbits. J. Comp. Pathol. 67:87-105.
62. Specter, F. C., E. R. Kern, J. Palmer, R. Kaiwar, T. A. Cha, P. Brown, and R. R. Spaete. 1998. Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs. J. Infect. Dis. 177:1143-1154.
63. Stanberry, L. R., E. R. Kern, J. T. Richards, T. M. Abbott, and J. C. Overall, Jr. 1982. Genital herpes in guinea pigs: pathogenesis of the primary infection and description of recurrent disease. J. Infect. Dis. 146:397-404.
64. Stanberry, L. R., S. L. Spruance, A. L. Cunningham, D. I. Bernstein, A. Mindel, S. Sacks, S. Tyring, F. Y. Aoki, M. Slaoui, M. Denis, P. Vandepapeliere, and G. Dubin. 2002. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347:1652-1661.
65. Velders, M. P., S. McElhiney, M. C. Cassetti, G. L. Eiben, T. Higgins, G. R. Kovacs, A. G. Elmishad, W. M. Kast, and L. R. Smith. 2001. Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. Cancer Res. 61:7861-7867.
66. Wachsman, M., L. Aurelian, C. C. Smith, B. R. Lipinskas, M. E. Perkus, and E. Paoletti. 1987. Protection of guinea pigs from primary and recurrent herpes simplex virus (HSV) type 2 cutaneous disease with vaccinia virus recombinants expressing HSV glycoprotein D. J. Infect. Dis. 155:1188-1197.
67. Wachsman, M., J. H. Luo, L. Aurelian, and E. Paoletti. 1992. Protection from herpes simplex virus type 2 is associated with T cells involved in delayed type hypersensitivity that recognize glycosylation-related epitopes on glycoprotein D. Vaccine 10:447-454.
68. Whaley, K. J., L. Zeitlin, R. A. Barratt, T. E. Hoen, and R. A. Cone. 1994. Passive immunization of the vagina protects mice against vaginal transmission of genital herpes infections. J. Infect. Dis. 169:647-649.
69. + CTL directed against herpes simplex virus-infected cells. J. Immunol. 162: 6100-6106.
70. York, L. J., D. P. Giorgio, and E. M. Mishkin. 1995. Immunomodulatory effects of HSV2 glycoprotein D in HSV1-infected mice: implications for immunotherapy of recurrent HSV infection. Vaccine 13:1706-1712.
71. Zeitlin, L., K. J. Whaley, P. P. Sanna, T. R. Moench, R. Bastidas, A. De Logu, R. A. Williamson, D. R. Burton, and R. A. Cone. 1996. Topically applied human recombinant monoclonal IgG1l antibody and its Fab and F(ab′)2 fragments protect mice from vaginal transmission of HSV-2. Virology 225: 213-215.
72. Zheng, B., F. L. Graham, D. C. Johnson, T. Hanke, M. R. McDermott, and L. Prevec. 1993. Immunogenicity in mice of tandem repeats of an epitope from herpes simplex gD protein when expressed by recombinant adenovirus vectors. Vaccine 11:1191-1198.